Chocarro, L.; Bocanegra, A.; Blanco, E.; Fernández-Rubio, L.; Arasanz, H.; Echaide, M.; Garnica, M.; Ramos, P.; Piñeiro-Hermida, S.; Vera, R.;
et al. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells 2022, 11, 2351.
https://doi.org/10.3390/cells11152351
AMA Style
Chocarro L, Bocanegra A, Blanco E, Fernández-Rubio L, Arasanz H, Echaide M, Garnica M, Ramos P, Piñeiro-Hermida S, Vera R,
et al. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells. 2022; 11(15):2351.
https://doi.org/10.3390/cells11152351
Chicago/Turabian Style
Chocarro, Luisa, Ana Bocanegra, Ester Blanco, Leticia Fernández-Rubio, Hugo Arasanz, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Piñeiro-Hermida, Ruth Vera,
and et al. 2022. "Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor" Cells 11, no. 15: 2351.
https://doi.org/10.3390/cells11152351
APA Style
Chocarro, L., Bocanegra, A., Blanco, E., Fernández-Rubio, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Piñeiro-Hermida, S., Vera, R., Escors, D., & Kochan, G.
(2022). Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells, 11(15), 2351.
https://doi.org/10.3390/cells11152351